ASND - Ascendis Pharma AS - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ASND is currently covered by 14 analysts with an average price target of $234.77. This is a potential upside of $59.37 (33.85%) from yesterday's end of day stock price of $175.4.

Ascendis Pharma AS's activity chart (see below) currently has 230 price targets and 217 ratings on display. The stock rating distribution of ASND is 12.2% HOLD and 87.8% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 54.69% with an average time for these price targets to be met of 352.95 days.

Highest price target for ASND is $289, Lowest price target is $153, average price target is $220.29.

Most recent stock forecast was given by DAVID LEBOWITZ from CITI on 10-Jul-2025. First documented stock forecast 22-Feb-2015.

Currently out of the existing stock ratings of ASND, 10 are a HOLD (12.2%), 72 are a BUY (87.8%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$243

$68.04 (38.89%)

$207

6 days ago
(10-Jul-2025)

6/12 (50%)

$68.04 (38.89%)

536

Buy

$250

$75.04 (42.89%)

$250

14 days ago
(02-Jul-2025)

19/22 (86.36%)

$75.82 (43.53%)

221

Buy

$224

$49.04 (28.03%)

$180

1 months 4 days ago
(12-Jun-2025)

3/11 (27.27%)

$53.2 (31.15%)

789

Buy

$216

$41.04 (23.46%)

$201

1 months 8 days ago
(08-Jun-2025)

11/14 (78.57%)

$42.85 (24.75%)

268

Buy

$200

$25.04 (14.31%)

$200

2 months 5 days ago
(11-May-2025)

15/19 (78.95%)

$45.57 (29.51%)

273

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ASND (Ascendis Pharma AS) average time for price targets to be met?

On average it took 352.95 days on average for the stock forecasts to be realized with a an average price target met ratio 54.69

Which analyst has the current highest performing score on ASND (Ascendis Pharma AS) with a proven track record?

PAUL CHOI

Which analyst has the most public recommendations on ASND (Ascendis Pharma AS)?

Paul Choi works at GOLDMAN SACHS and has 6 price targets and 5 ratings on ASND

Which analyst is the currently most bullish on ASND (Ascendis Pharma AS)?

Derek Archila with highest potential upside - $114.04

Which analyst is the currently most reserved on ASND (Ascendis Pharma AS)?

Tiago Fauth with lowest potential downside - -$85.96

Ascendis Pharma AS in the News

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025

COPENHAGEN, Denmark, July 07, 2025 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced two oral presentations at ENDO 2025, the annual meeting of the Endocrine Society being held July 12-15, 2025, in San Francisco. Dr. Aliya Khan will present new data from Week 156 of the Company’s Phase 3 PaTHway Trial demonstrating the...

Ascendis Pharma AS (ASND) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...

Total Revenue: EUR101 million for the first quarter. YORVIPATH Revenue: EUR44.7 million in Q1, up from EUR13.6 million in Q4 2024. SKYTROFA Revenue: EUR51.3 million for the quarter. R&D Expenses: EUR86.6 million in Q1 2025, compared to EUR70.7 million in Q1 2024. SG&A Expenses: EUR101 million in Q1 2025, up from EUR66.8 million in Q1...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?